Following an international selection process lasting several years, Lengnau was chosen as the new production site. It is planned to manufacture recombinant coagulation factors to treat hemophilia (bleeding disorder). The new plant in the industrial park Lengnaumoos will create more than 300 new jobs and will stimulate investments of approx. 1 billion Swiss Francs over a period of 5 years.
(click to enlarge)
CSL Behring already has a strong presence in Bern. At the site in Bern Wankdorf, the company operates the largest production site for the manufacture of plasma-derived therapies to treat rare and serious medical disorders.
The planned investment in Lengnau complements the production expansion projects at the CSL Behring sites in Germany, Australia and the U.S. It is part of the ongoing global capacity expansion and is of vital importance for the company's long-term growth strategy.
The proximity to and the availability of professional expertise at the existing production site of CSL Behring in Switzerland were key factors for the strategic choice of Lengnau as the location for the new recombinant production site.
CSL Behring obtained the building property in construction right in the industrial park Lengnaumoos. In early 2015, construction work started. The new site will start production in 2020 and operate independently from the site in Bern.
Architecture and General Planning: ANS Architekten and Planer SIA AG, Worb, Switzerland
General Planning Plant Construction: M+W Central Europe Gmbh, Stuttgart, Germany
ARGE (consortium), our local partners: